
Centogene N.V. CNTG
Annual report 2023
added 12-27-2025
Centogene N.V. DSO Ratio 2011-2026 | CNTG
Annual DSO Ratio Centogene N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 145 | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 145 | 145 | 145 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | ||
|
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 203.06 | -0.38 % | $ 22.5 B | ||
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
94.7 | $ 4.29 | -8.72 % | $ 5.71 M | ||
|
Fulgent Genetics
FLGT
|
87 | $ 18.68 | -0.53 % | $ 575 M | ||
|
Castle Biosciences
CSTL
|
50.2 | $ 20.7 | -1.48 % | $ 600 M | ||
|
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
72.7 | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | ||
|
ICON Public Limited Company
ICLR
|
63.4 | $ 146.18 | -2.49 % | $ 11.5 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M | ||
|
Guardant Health
GH
|
46.1 | $ 131.62 | 0.55 % | $ 16.5 B | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 22.97 | -2.92 % | $ 1.22 B | ||
|
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | ||
|
Interpace Biosciences
IDXG
|
66.9 | $ 1.6 | -3.03 % | $ 7.08 M | ||
|
Illumina
ILMN
|
66.8 | $ 160.97 | -3.15 % | $ 25 B | ||
|
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | ||
|
National Research Corporation
NRC
|
29.4 | $ 18.79 | - | $ 421 M | ||
|
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | ||
|
Natera
NTRA
|
48.3 | $ 212.07 | -3.27 % | $ 29 B | ||
|
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | ||
|
Pacific Biosciences of California
PACB
|
71.8 | $ 1.31 | -2.96 % | $ 393 M | ||
|
Lantheus Holdings
LNTH
|
80.5 | $ 104.52 | 0.19 % | $ 7.05 B | ||
|
Charles River Laboratories International
CRL
|
65 | $ 187.51 | -0.29 % | $ 9.29 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 467.34 | -1.63 % | $ 13.5 B | ||
|
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | ||
|
Mettler-Toledo International
MTD
|
66.4 | $ 1 131.49 | -0.86 % | $ 23.3 B | ||
|
NeoGenomics
NEO
|
77.7 | $ 11.15 | -2.79 % | $ 1.43 B | ||
|
Myriad Genetics
MYGN
|
52.3 | $ 4.33 | -6.48 % | $ 401 M | ||
|
Personalis
PSNL
|
63.8 | $ 9.59 | 1.8 % | $ 856 M | ||
|
Twist Bioscience Corporation
TWST
|
44.5 | $ 76.17 | 2.86 % | $ 4.56 B | ||
|
Senseonics Holdings
SENS
|
1.04 | $ 7.18 | -2.05 % | $ 300 M | ||
|
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
27 | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
57.7 | $ 2.05 | -1.91 % | $ 4.71 M | ||
|
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 266.16 | 0.34 % | $ 22.1 B | ||
|
Thermo Fisher Scientific
TMO
|
70 | $ 469.34 | -1.33 % | $ 177 B | ||
|
Trinity Biotech plc
TRIB
|
87.2 | $ 0.65 | -3.7 % | $ 233 M | ||
|
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
66.6 | $ 9.1 | -1.57 % | $ 1.97 B | ||
|
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M |